A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

Phase 1 Completed 105 enrolled TYK Medicines, Inc

NaSingle-groupOpen-labelTreatment

The primary objective of this study is to evaluate the safety and tolerability of TY-9591, with dose-escalation stage and dose-expansion stage.

Evaluation	Drug	Modality	Dose	Route
Subject	TY-9591	Unknown	20 mg	Oral
Subject	TY-9591	Unknown	40 mg	Oral
Subject	TY-9591	Unknown	80 mg	Oral
Subject	TY-9591	Unknown	120 mg	Oral
Subject	TY-9591	Unknown	160 mg	Oral
Subject	TY-9591	Unknown	200 mg	Oral